Patients with Crohn’s achieve tight disease control with long-term Rinvoq treatment

Patients with Crohn’s disease in their second year of treatment with Rinvoq showed sustained improvements in disease control, deep remission and quality of life, according to research presented at the American College of Gastroenterology Annual Scientific Meeting.Geert D’Haens, MD, PhD, from Amsterdam University Medical Centers in the Netherlands, said the CELEST phase 2 study showed that more patients with CD achieved endoscopic and clinical remission with Rinvoq (upadacitinib, AbbVie) compared with placebo after 16 weeks of treatment. Researchers also observed improved outcomesRead More

Share on facebook
Share on twitter
Share on linkedin